Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
02 February 2021 - 12:49AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca agrees to divest Viela shareholding
1 February 2021 12:15 GMT
AstraZeneca agrees to divest Viela shareholding
AstraZeneca has agreed, subject to certain limited exceptions, to
divest its 26.7% ownership in Viela Bio, Inc. (Viela), as part of
the proposed acquisition of Viela by Horizon Therapeutics
plc (Nasdaq: HZNP).
AstraZeneca is anticipating to receive cash proceeds and profit of
c.$760-$780m upon closing for the sale of the holding, which will
be recorded in Reported and Core Other Operating Income and Expense
in the Company's financial statements. The divestment is expected
to complete by the end of the first quarter of 2021.
The divestment does not impact the Company's financial guidance for
2020. Guidance for 2021 is anticipated to be issued with full-year
2020 results on 11 February 2021.
Viela
Viela (Nasdaq: VIE), headquartered in Gaithersburg, Maryland, is a
biotechnology company dedicated to the discovery, development and
commercialisation of novel treatments for autoimmune and severe
inflammatory diseases. Viela was founded in 2018 as a spinout from
AstraZeneca, with clinical and pre-clinical projects from
AstraZeneca's inflammation and autoimmunity pipeline.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
AstraZeneca contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
01 February
2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024